All eyes are on the ASX on Tuesday morning after share markets slumped lower again on Monday.
Indexes closed in the red yesterday afternoon and are expected to open lower again this morning thanks to slumping commodity prices and volatility in US share markets.
Shifting markets have pushed major ASX shares like BHP Group Ltd (ASX: BHP), Westpac Banking Corp (ASX: WBC), and CSL Ltd (ASX: CSL) into the spotlight this week.
Here's the latest out of the three ASX shares, and what brokers tip next.
The ASX mining giant's shares have dropped around 5% over the past week, to $57.21 at the time of writing.
Weaker commodity prices, particularly lower copper and iron ore prices, are dragging down BHP shares.
According to Trading Economics data, copper declined to around US$6 per pound on Monday, reaching its lowest levels since June, amid concerns about AI shares and a strengthening US dollar weighed heavily on the metal. Copper is now down around 9% over the past month.
Iron ore is facing similar headwinds. Iron ore dropped below CNY 650 per ton on Monday, reaching its lowest levels since October 2022 thanks to concerns over weakening steel demand toward the end of the year.
Analysts are also concerned about ongoing commodity price weakness but expect margin compression to stabilise as Chinese steel demand normalises.
TradingView data shows the majority of analysts (11 out of 18) have a hold rating on BHP shares. Another five rate the shares as a strong buy, and two rate them a sell/strong sell.
The average $62.42 target price implies an upside of around 9% at the time of writing.
Westpac shares have climbed around 2% higher over the past week, to $37.77 at the time of writing. They're also up around 7% over the past month.
It looks like the latest positive sentiment continues to be driven by the company's FY26 results earlier this month.
On the 2nd of November, Westpac reported a statutory net profit of $6.8 billion for FY26, down 1% from the previous year. Excluding notable items, net profit was broadly flat at $7 billion.
The bank's lending operations saw stronger performance. Total loans increased 5% over the year and customer deposits climbed 6%. The bank performed particularly well in both business and institutional lending, where balances increased 12% and 18%, respectively.
The bank finished the year with a common equity tier 1 capital ratio of 12.5%, which was comfortably above its target.
The result pleased investors, but analysts are still concerned that the bank's valuation is stretched and that market headwinds, including deposit competition and a slower property market, are too strong to justify buying.
TradingView data shows eight out of 16 analysts have a sell/strong sell rating. Another seven rate the bank as a hold and one has a strong buy rating.
The $32.99 average target price implies a 13% downside at the time of writing.
CSL shares have staged an impressive recovery over the past three months, recouping all the losses shed earlier this year.
At the time of writing, the shares are $202.52 each, which is around 18% higher for the year to date and 12% higher than 12 months ago.
The shares sprung back into life after the ASX biotech company posted an impressive FY26 result on the 18th of August, including total revenue of US$15.8 billion and underlying NPAT of US$3.1 billion. Management described FY26 as a 'reset year' for CSL, and said that it expects FY27 to be the year the company returns to growth.
On the 5th of October, CSL also announced a new deal with Alentis Therapeutics for lixudebart, a treatment targeting rare kidney and liver conditions. CSL is expected to make an initial upfront payment of US$355 million, with the agreement valued up to US$1.6 billion.
Later the same month, on the 21st of October, the company announced Deborah Waterhouse as its new CEO and Managing Director effective from 1 February 2027.
Experts are bullish that CSL can deliver on its FY27 guidance of a 5% increase in underlying NPAT, although after the latest strong rally, the average target price sits a little below the current share price.
TradingView data shows that 10 out of 19 analysts have a buy/strong buy rating on the shares. Another eight rate the shares as a hold and one has a sell rating.
The average $200.57 target price implies around a 1% downside, at the time of writing.
The post BHP, Westpac, CSL shares: Buy, sell, or hold? appeared first on The Motley Fool Australia.
Motley Fool contributor Samantha Menzies has positions in BHP Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended BHP Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026